Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Fish and Richardson
McKesson
Daiichi Sankyo
Federal Trade Commission
Cipla
Dow
Boehringer Ingelheim
Farmers Insurance
UBS

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,967,011

« Back to Dashboard

Which drugs does patent 7,967,011 protect, and when does it expire?


Patent 7,967,011 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in twenty-three countries.

Summary for Patent: 7,967,011

Title:Inhalation device
Abstract: Actuator for an inhaler for delivering medicament by inhalation, having a mouthpiece for guiding medicament to the mouth of a user; and a removable protection cap for the mouthpiece. The cap is secured to the mouthpiece by a cap retaining member that engages a mating recess in the mouthpiece outer periphery. The cap includes at least one release button arranged to provide an elastic deformation of the cap inner periphery that disengages the cap retaining member from the recess.
Inventor(s): Hodson; Darren (Shropshire, GB), Rasmussen; Jorgen (Struer, DK)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/346,558
Patent Claim Types:
see list of patent claims
Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AstrazenecaSYMBICORTbudesonide; formoterol fumarate dihydrateAEROSOL, METERED;INHALATION021929-001Jul 21, 2006RXYesYes► Subscribe► Subscribe► SubscribeY
AstrazenecaSYMBICORTbudesonide; formoterol fumarate dihydrateAEROSOL, METERED;INHALATION021929-002Jul 21, 2006RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,967,011

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9704185Nov 14, 1997

Non-Orange Book Patents for Patent: 7,967,011

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,805,116 Inhalation device► Subscribe
8,584,668Inhalation device► Subscribe
7,743,765Inhalation device► Subscribe
7,367,333Inhalation device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,967,011

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2614628► Subscribe
Brazil9814964► Subscribe
Canada2309732► Subscribe
Canada2310224► Subscribe
Canada2614626► Subscribe
Canada2616784► Subscribe
Canada2616785► Subscribe
Canada2616786► Subscribe
China1285762► Subscribe
China1188185► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Citi
Chubb
Chinese Patent Office
Merck
Johnson and Johnson
Queensland Health
Fish and Richardson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot